Down syndrome (Trisomy 21)

Why a paediatric-neurology view of Down syndrome matters

Down syndrome is most often discussed in cardiac, endocrine and growth terms — and those areas of surveillance matter — but the brain has its own story across the lifespan, and that story is what makes a paediatric-neurology-aware view valuable. From infancy onwards, families navigate cognitive support, early intervention, epilepsy risk (notably infantile spasms in the first year), co-occurring autism, sleep-disordered breathing, behavioural features and mental health, and — across the longer arc — the high lifetime risk of early-onset Alzheimer's disease driven by APP gene triplication on chromosome 21.

Our approach is to map the neurological strands of Down syndrome alongside the cardiac, endocrine and growth strands, and to integrate them in a single plan that grows with the child rather than reverts to symptom-by-symptom management.

Cognitive trajectory and educational support

Most children with Down syndrome have mild-to-moderate intellectual disability, with considerable individual variation. Strong long-term educational and developmental outcomes are very possible with structured early intervention, school inclusion where appropriate, focused language and literacy support (visual learning is often a relative strength), and adapted approaches to numeracy and executive function. Vineland-3 and age-appropriate cognitive tools are used to map the developmental profile and to track change over time.

A small but important minority of children show a marked plateau or regression — which should not be dismissed as part of the syndrome. Sleep-disordered breathing, hypothyroidism, coeliac disease, vitamin deficiencies, depression, autism spectrum features and (in young adults) the earliest cognitive features of Alzheimer's disease all need to be considered when a child or young person with Down syndrome stops progressing as expected.

Epilepsy and infantile spasms

Children with Down syndrome have a higher risk of epilepsy across life than the general paediatric population. The most important early-life pattern is infantile spasms, which occur in roughly 5–10% of children with Down syndrome and respond well to early treatment with ACTH or vigabatrin. Outcomes after Down-syndrome-associated infantile spasms are generally better than for other aetiologies — but only when treatment is started promptly. Parents and primary-care clinicians need to recognise the classical spasm pattern and seek urgent EEG and treatment.

Later-onset epilepsies — including generalised epilepsy and, in adulthood, late-onset epilepsy associated with Alzheimer-type cognitive change — also need recognition and management.

Co-occurring autism, ADHD and behaviour

Autism spectrum disorder co-occurs in approximately 15–20% of children with Down syndrome — significantly higher than the general-population rate. Recognising it matters because the educational, behavioural and family-support strategy changes. The dual diagnosis is often missed because both conditions affect communication and behaviour, and signs are sometimes attributed to Down syndrome alone.

ADHD, anxiety, depression and obsessive-compulsive features are also more common, and benefit from structured screening and appropriate management.

Sleep, OSA and behaviour

Obstructive sleep apnoea is common in Down syndrome — by some estimates affecting 50–80% of children — and is often undertreated. It affects cognition, behaviour, mood, growth and cardiovascular outcomes. Routine polysomnography in the first years is recommended in current guidelines, with adenotonsillectomy, CPAP, weight management and orthognathic input as needed. A child with Down syndrome who is not progressing as expected, or whose behaviour has deteriorated, should have sleep-disordered breathing actively excluded.

Long-term brain — early-onset Alzheimer's risk

Triplication of the APP gene on chromosome 21 means that virtually all adults with Down syndrome accumulate Alzheimer-type pathology decades earlier than the general population. Clinical dementia onset typically occurs in the fourth to sixth decade. This is a long-term consideration that increasingly informs lifespan planning, surveillance from young adulthood, lifestyle counselling, and — for some families — discussion of the emerging anti-amyloid therapies being trialled specifically in the Down-syndrome population.

How an educational review can help

Down-syndrome families often have excellent paediatric and cardiac care, but the neurological and developmental strands can be more fragmented. An educational review can pull together the current literature on cognitive support, infantile spasm vigilance, autism screening, sleep-disordered breathing, and the lifelong brain trajectory, and prepare focused questions for the treating team.

It is educational — not a diagnosis, treatment or prescription — and does not replace the care of your child's own clinicians.